Pierelli L, Menichella G, Scambia G, Teofili L, Iovino S, Serafini R, Benedetti Panici P, Salerno G, Rumi C, Zini G
Centro Richerche per la Manipolazione dei Costituenti Ematici, Catholic University, Rome, Italy.
Bone Marrow Transplant. 1994 Jul;14(1):23-30.
We tested in vitro the effect of recombinant human erythropoietin (rhEPO) plus recombinant human G-CSF (rhG-CSF) on purified human CD34+ haemopoietic progenitors (HP) and in vivo in patients who had undergone anti-cancer chemotherapy for advanced ovarian cancer. In this preliminary experience we found that, in vitro, rhEPO potentiates the effect of rhG-CSF on HP growth and differentiation toward the granulocyte-macrophage lineage. rhEPO plus rhG-CSF produced in vitro a proliferative stimulus of HP which represents 26% of the maximum stimulation obtained using IL-1, IL-3, IL-6, G-CSF, GM-CSF and stem cell factor in combination. In the patients treated with rhEPO plus rhG-CSF after chemotherapy, we observed a favourable trend for platelet and neutrophil recoveries compared with a control group treated with rhG-CSF alone and a significantly higher haematocrit nadir was observed in the rhEPO plus rhG-CSF series. In the patients treated with rhEPO plus rhG-CSF we observed a significant increase of circulating colony-forming unit granulocyte-macrophage (CFU-GM) and burst forming unit-erythroid (BFU-e) compared with the rhG-CSF series. Our results, in vitro and in vivo, encourage the in vivo use of rhEPO plus rhG-CSF to improve blood cell recoveries of patients who have undergone conventional or high-dose chemotherapy. Moreover, rhEPO plus rhG-CSF was demonstrated to be a good HP mobilising treatment for blood stem cell collection after chemotherapy.
我们在体外测试了重组人促红细胞生成素（rhEPO）加重组人粒细胞集落刺激因子（rhG-CSF）对纯化的人CD34+造血祖细胞（HP）的作用，并在晚期卵巢癌抗癌化疗患者中进行了体内测试。在这项初步研究中，我们发现，在体外，rhEPO可增强rhG-CSF对HP向粒细胞-巨噬细胞谱系生长和分化的作用。rhEPO加rhG-CSF在体外产生了HP的增殖刺激，这相当于联合使用IL-1、IL-3、IL-6、G-CSF、GM-CSF和干细胞因子所获得的最大刺激的26%。在化疗后接受rhEPO加rhG-CSF治疗的患者中，与单独接受rhG-CSF治疗的对照组相比，我们观察到血小板和中性粒细胞恢复有良好趋势，并且在rhEPO加rhG-CSF组中观察到血细胞比容最低点明显更高。与rhG-CSF组相比，在接受rhEPO加rhG-CSF治疗的患者中，我们观察到循环粒细胞-巨噬细胞集落形成单位（CFU-GM）和红系爆式集落形成单位（BFU-e）显著增加。我们的体内外研究结果鼓励在体内使用rhEPO加rhG-CSF来改善接受传统或高剂量化疗患者的血细胞恢复。此外，rhEPO加rhG-CSF被证明是化疗后采集血液干细胞的良好HP动员治疗方法。
